ArticleScientific reports2025
Effectiveness and safety of methylprednisolone combination with abrocitinib compared to methylprednisolone combination with azathioprine in bullous pemphigoid: a retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report.Frontiers in immunology · 2026Article
- Upadacitinib for the treatment of refractory bullous pemphigoid: a case report and literature review.Frontiers in immunology · 2026Review
- Tyrosine kinase signaling pathways as therapeutic targets in autoimmune subepidermal blistering skin diseases (pemphigoid diseases).Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bullous pemphigoid (BP) is an autoimmune skin disorder involving Th2-related inflammation. Abrocitinib is a JAK1 inhibitor and a promising therapeutic option for BP as it can effectively attenuate Th2-associated inflammation. This study compared the efficacy and safety of methylprednisolone combined with abrocitinib (abrocitinib group) versus methylprednisolone combined with azathioprine (conventional group) in BP treatment. The median time for disease control and achievement of minimal therapy in the abrocitinib group was notably reduced compared with those in the conventional group [7 vs. 11 days (p = 0.0006) and 100 versus days (p < 0.0001), respectively]. Additionally, the median cumulative methylprednisolone amount (at the time of achieving minimal therapy) in the abrocitinib group was remarkably reduced compared to that in the conventional group (1568 versus 2170 mg; p < 0.0001). Moreover, the abrocitinib group exhibited a more rapid decrease in Bullous Pemphigoid Disease Area Index (BPDAI) and itching Numeric Rating Scale (NRS) scores. At week 36, 11 patients (52.4%) in the abrocitinib group achieved complete remission (CR) off therapy, which was significantly higher than 2 patients (9.1%) in the conventional group (p = 0.003). There were no serious abrocitinib-associated adverse effects. Methylprednisolone combined with abrocitinib appeared more effective than methylprednisolone combined with azathioprine in controlling disease progression and tapering corticosteroids in BP patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.